Research scientists identified vulnerable site on multiple coronaviruses that could be targeted to prevent future pandemics.
On Feb. 10, 2022, Scripps Research announced that the COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the…
H5N1 highly pathogenic avian influenza (HPAI) Reported in indiana
On Feb. 9, 2022, the Indiana Department of Health confirmed that a case of H5N1 highly pathogenic avian…
USDA confirmed highly pathogenic avian influenza commercial turkey flock in Dubois County, Indiana
On Feb. 9, 2022, the U.S. Department of Agricultureï¾’s National Veterinary Services Laboratories confirmed the presence of highly…
Nasal spray booster keeps COVID-19 at bay
On Feb. 8, 2022, Howard Hughes Medical Institute (HHMI) announced The program, named Codetta, can read the genome…
Moderna announced new supply agreement with Colombia for additional 10.8 million doses of COVID-19 vaccine
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
Merck and Ridgeback announced 3.1 million courses of molnupiravir investigational oral antiviral COVID-19 medicine supplied to U.S. Government
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…
Study suggested COVID-19 vaccines do not reduce fertility
On Feb. 8, 2022, a research team led at Boston University School of Public Health reported on links…
First-in-human implant of ‘closed-loop’ bioelectronic research system begun for Parkinson’s-like Multiple Systems Atrophy
On Feb. 8, 2022, researchers at Oxford University announced they had implanted a novel closed-loop research platform for…
NIH-funded study suggested COVID-19 increased risk of pregnancy complications
On Feb. 4, 2022, the NIH announced a study that showed pregnant women with COVID-19 appeared to be…
COVID-19 infections increased risk of heart conditions
On Feb. 7, 2022, researchers at Washington University School of Medicine in St. Louis announced an analysis of…
Scientists demonstrated DNA from terrestrial animals can be filtered, amplified and sequenced from air
On Feb. 7, 2022, scientists working with the Queen Mary University of London and the London Genome Centre…
Common skin bacteria found beneficial against drying, aging
On Feb. 4, 2022, the NIH reported that Staphylococcus epidermidis produces enzymes, known as sphingomyelinase, that help the…
Research collaboration launched to focus on repurposing existing anti-viral therapies to treat COVID-19
On Feb. 4, 2022, a new ï¾£1.6m collaborative project was launched to rapidly identify new treatments for COVID-19….
How sneezing hamsters sparked a COVID outbreak in Hong Kong
On Feb. 4, 2022, pet hamsters probably carried the Delta variant of SARS-CoV-2 into Hong Kong and sparked…
CDC’s ACIP issued recommendation for use of Moderna COVID-19 vaccine in adults aged =18 years
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
T2 Biosystems T2SARS-CoV-2 panel detects Omicron subvariants
On Feb. 3, 2022, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected Omicron COVID-19 subvariants BA.1, BA.2, and…
New Zealand’s Medsafe granted provisional approval for Novavax’ COVID-19 vaccine
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
NIAID Pandemic Preparedness Plan targeted ‘prototype’ and priority pathogens
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
FDA approved first generic of Restasis
On Feb. 2, 2022, the U.S. Food and Drug Administration announced it had approved the first generic of…
Study of Penn patients with decade-long leukemia remissions after CAR T cell therapy revealed new details about persistence of personalized ‘Living Drug’ cells
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
Artificial Intelligence | Biotechnology | CRISPR | Genomics | Life Science History | Life Science News | Medicine | NIH | Non-Profit Research | Therapeutics | Vaccine
Cancer MoonShot program reignited
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
Pfizer and BioNTech initiated rolling submission for EUA of COVID-19 vaccine in children 6 months through 4 years of age
On Feb. 1, 2022, Pfizer and BioNTech announced that following a request from the U.S. Food and Drug…
Moderna received full U.S. FDA approval for COVID-19 vaccine Spikevax
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA)Â had approved the Biologics License…
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
InteliSwabï¾® COVID-19 rapid tests receive U.S. FDA authorization for pediatric use
On Jan. 31, 2022, OraSure Technologies announced that its InteliSwabï¾® COVID-19 rapid tests had been authorized by the…
Veru announced FDA Grant of Fast Track Designation for Sabizabulin for treatment of hospitalized COVID-19 patients
On Jan. 31, 2022, Veru announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track…
Novavax and Israel announced advance purchase agreement for supply of COVID-19 vaccine
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
WHO and Viamo provided critical access to COVID-19 information to the next billion digital users via their mobile phones
On Jan. 28, 2022, the WHO announced that COVID-19 information had reached 1,292,209 people through Viamoï¾’s 3-2-1 Platform…
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…